Tiziana Life Sciences CEO purchases 163,400 shares; intranasal foralumab shows promise in treating multiple sclerosis.
Quiver AI Summary
Tiziana Life Sciences, a biotechnology company focused on immunomodulation therapies, announced that its CEO, Ivor Elrifi, has acquired an additional 163,400 shares of the company's stock, increasing his total holdings to 357,848 shares. The company is developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody currently undergoing clinical trials for treating non-active secondary progressive multiple sclerosis (na-SPMS). In a recent Expanded Access Program, all 14 treated patients showed either improvement or stability in their condition after six months. Foralumab is unique as the only fully human anti-CD3 monoclonal antibody in clinical development and represents a novel method for addressing neuroinflammatory and neurodegenerative diseases. Tiziana is leveraging unique drug delivery technologies to enhance immunotherapy efficacy and safety compared to traditional intravenous methods.
Potential Positives
- CEO Ivor Elrifi's purchase of 163,400 shares in the open market signals confidence in the company's future and aligns his financial interests with those of shareholders.
- Intranasal foralumab is uniquely positioned as the only fully human anti-CD3 monoclonal antibody currently in clinical development, highlighting its innovative nature in the biotech industry.
- The ongoing clinical trials, including a Phase 2a study, indicate positive initial responses in patients with non-active secondary progressive multiple sclerosis, supporting the potential efficacy of foralumab.
- Tiziana Life Sciences' patented technology for alternative routes of immunotherapy could open new avenues for treatment, representing a significant competitive advantage in the biopharmaceutical market.
Potential Negatives
- CEO's significant stock purchase may raise concerns among investors about the company's financial stability or the timing of such purchases, potentially indicating a lack of confidence in the company's market performance.
- The limited scope of current clinical trials (only 14 patients dosed) may reflect challenges in progressing the drug development pipeline, possibly hindering broader acceptance and investment.
- The press release does not provide detailed information on timelines, endpoints, or results from ongoing clinical trials, leaving investors with uncertainties about the future of intranasal foralumab and the company's overall strategy.
FAQ
What is Tiziana Life Sciences, Ltd. known for?
Tiziana Life Sciences, Ltd. is a biotechnology company developing breakthrough immunomodulation therapies, focusing on intranasal foralumab.
Who is the CEO of Tiziana Life Sciences?
The CEO of Tiziana Life Sciences is Ivor Elrifi, who recently purchased 163,400 shares of the company's stock.
What is foralumab?
Foralumab is a fully human anti-CD3 monoclonal antibody designed to stimulate T regulatory cells and is being studied for multiple sclerosis.
What clinical trials is foralumab involved in?
Foralumab is currently involved in an open-label Expanded Access Program and a Phase 2a randomized clinical trial for non-active secondary progressive MS.
Why is Tiziana's nasal approach innovative?
Tiziana's nasal approach aims to improve efficacy and safety of immunotherapy compared to traditional intravenous delivery methods.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TLSA Hedge Fund Activity
We have seen 12 institutional investors add shares of $TLSA stock to their portfolio, and 22 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DAUNTLESS INVESTMENT GROUP, LLC removed 682,684 shares (-20.0%) from their portfolio in Q3 2025, for an estimated $1,474,597
- MARSHALL WACE, LLP added 243,643 shares (+999.8%) to their portfolio in Q3 2025, for an estimated $526,268
- MILLENNIUM MANAGEMENT LLC added 240,814 shares (+inf%) to their portfolio in Q3 2025, for an estimated $520,158
- CITADEL ADVISORS LLC removed 198,990 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $429,818
- OMERS ADMINISTRATION CORP removed 144,900 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $228,942
- HRT FINANCIAL LP removed 84,106 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $181,668
- SIMPLEX TRADING, LLC removed 67,251 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $145,262
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his current purchased shares total to 357,848.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases. [1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com .
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email:
[email protected]
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
